Exclusive Content

In anticipation of the Pharmaceutical Traceability Forum, we spoke with Matt Sample and Christopher Howell about the top pharmaceutical challenges surrounding Serialization: Aggregation and CMO Integration. Both speakers shared their unique perspectives on the topic and also expressed what they were most excited to learn about at the upcoming event.

In advance of the Forum, we spoke with an elite representative from the wholesaler side of pharmaceutical shipping about the plans his company has and the challenges he’s facing. Take these into consideration today for best results 7 years from now.

Pharma IQ spoke with Mark Davison, Chief Executive Officer at Blue Sphere Health Ltd, and Vetter Pharma to gain insight into SME pharma & biotechs for serialization, as well as strategies that CMOs can implement to succeed in serialization.

Before you hear from these great speakers at the Forum, read their thoughts on serialization within the life sciences industry. We sat down with speakers from top companies such as AmerisourceBergen, Merck & Co., NC Mutual Wholesale Drug Company and Neurocrine Biosciences, find out what they had to say!

With time running low, Pharma Logistics IQ tracks the state of the industry’s serialization projects. This year’s research report maps out and measures the changes in consensus as the industry advances closer to an entirely track-and-trace pharmaceutical environment. Sections covered:

This is the second article in a series looking at how to avoid the supply risk when working with CMOs on serialization. In this article I will discuss another six learnings covering everything from resource-planning to clarifying your RACI.

Pharma IQ have created an updated serialisation printable world map to assist with your worldwide serialisation compliance strategies and help the industry prepare for these various approaching deadlines all over the globe.

Ahead of the 6th Pharmaceutical Traceability Forum, December 7 -8, we interviewed members of our speaker faculty on their immediate impressions of the FDA meeting that was held in August. Get your copy of this exclusive interview to find out what the FDA vision of the future is for 2023!

Effective data management is imperative to achieve regulatory compliance with a serialisation programme. Non-standard data exchange and integration methods are seen as one of the biggest hurdles in serialisation compliance.
In light of the data responsibilities expected within serialisation projects, Pharma IQ consults with a selection of experts on software best practices - data integration and implementation.

Pharma IQ collected the following market research to pinpoint the concerns and priorities of those in the more mature phases of serialization. Commentary supplied by Pasi Kemppainen, Executive Consultant, Pharma Serialization and Traceability.

The Drug Quality and Security Act (DQSA), was enacted by Congress on November 27, 2013. Title II of DQSA, the Drug Supply Chain Security Act (DSCSA), outlines steps to build an electronic, interoperable system to identify and trace certain prescription drugs as they are distributed in the United States. This will enhance FDA’s ability to help protect consumers from exposure to drugs that may be counterfeit, stolen, contaminated, or otherwise harmful. The system will also improve detection and removal of potentially dangerous drugs from the drug supply chain to protect U.S. consumers.

To help ensure you meet the November, 23, 2023 deadline, we created this interactive presentation that sheds light on the upcoming deadlines, requirements and other need-to-know information.

We created a map to provide an overview of various countries and their serialization journey, as global deadlines are approaching fast. By 2020, serialization is anticipated to cover 80% of the global drug supply. This map takes a look at the United States, European Union, Brazil, Turkey, Egypt, Australia, China, India, South Korea, Russia, and many more.